Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial.

ABSTRACT:

Aim

To evaluate the efficacy and safety of colchicine for improving metabolic and inflammatory outcomes in people with obesity and metabolic syndrome (MetS).

Materials and methods

Adults with obesity and MetS, but who did not have diabetes, were randomized to colchicine 0.6 mg or placebo capsules twice daily for 3 months. The primary outcome was change in insulin sensitivity (S_I ) as estimated by insulin-modified frequently sampled intravenous glucose tolerance tests. Secondary outcomes included changes in other metabolic variables and inflammatory markers.

Results

Of 40 participants randomized (21 colchicine, 19 placebo), 37 completed the trial. Compared with placebo, colchicine significantly reduced C-reactive protein (P <0.005), erythrocyte sedimentation

SUBMITTER: Demidowich AP 

PROVIDER: S-EPMC6570563 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature